Materials and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
- The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.J Urol. 2003; 170: 1872-1876
- Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.Urol Clin North Am. 2001; 28: 555-565
- Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results.J Urol. 2004; 172: 910-914
- Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.Int J Clin Oncol. 2015; 20: 171-175
- Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.Eur Urol. 2007; 51: 1175-1184
- Natural history of progression after PSA elevation following radical prostatectomy.JAMA. 1999; 281: 1591-1597
- Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.JAMA. 2005; 294: 433-439
- The clinical usefulness of prostate specific antigen: update 1994.J Urol. 1994; 152: 1358-1368
- Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.J Urol. 2009; 182: 2250-2255
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.Int J Radiat Oncol Biol Phys. 2006; 64: 1140-1150
- Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.Urology. 2008; 71: 136-140
- Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.World J Urol. 2013; 31: 299-304
- Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.Prostate Cancer Prostatic Dis. 2016; 19: 423-428
- Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the SEARCH Database.BJU Int. 2010; 105: 1541-1547
- Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.Urology. 2003; 61: 365-369
- Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.Cancer. 2004; 101: 2549-2556
- The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.BJU Int. 2006; 98: 540-543
- Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.Eur Urol. 2014; 65: 620-627
- Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.Cancer. 2007; 109: 1290-1295
- Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.Int J Radiat Oncol Biol Phys. 2002; 53: 297-303
- Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.J Urol. 2009; 181: 956-962
- Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.Urology. 2010; 76: 723-727
Research support: Department of Veterans Affairs, National Institute of Health R01CA100938 (WJA), NIH Specialized Programs of Research Excellence Grant P50 CA92131-01A1 (WJA), the Georgia Cancer Coalition (MKT), NIH K24CA160653.
Disclaimer: Views and opinions of, and endorsements by, the authors do not reflect those of the US Army or the Department of Veterans Affairs.
Financial Disclosure: The authors declare that they have no relevant financial interests.